This dinosaur still lumbers among us. Despite the efforts of health plans and Medicare to find a better payment methodology, so much of our health care system — such as the Current Procedural Terminology code — is entangled with FFS. It might take years, even decades, for FFS to go away.
The current slowdown in cost increases need not be an anomaly, says the Harvard professor and presidential campaign advisor. Keeping the trajectory going will take payment reform, greater investment in technology, and a reduction in the growth of the health care workforce.
The Affordable Care Act is changing business models, forging different stakeholder alliances, and generating new research — all of which alter the value conversation. It’s not just about dollars and cents anymore, but something more holistic. Payers are not the only ones who want to see real-world outcomes.
Scientists working for decades to unlock the secrets that will allow the immune system to fight cancer finally see results. The feeling among many experts is that we are closing in on a new era of cancer treatment, one that will feature immunotherapies. This does not come cheap, however.
They might bring better precision to the treatment of rheumatoid arthritis, beginning with enabling physicians to make earlier and more accurate diagnoses. This will not only lead to better outcomes but, on the business side, help insurers and PBMs better coordinate their efforts.
Minimally disruptive medicine might provide the sort of assistance that often overwhelmed patients need. This will especially help those with several chronic conditions, but anyone with a complicated health situation should benefit, say proponents. This could be the beginning of a cultural change in care.
Biologics and high-cost medications are becoming mainstream, creating different challenges for insurers
A summary of ECRI Institute’s Emerging Technology Evidence Report
The FDA wants to significantly shorten the development time for new medications by cutting years out of the R&D process
F. Randy Vogenberg, RPh, PhD
In two studies, Lymphoseek outperformed previous agents in identifying nodes containing metastatic malignancies
R. Blake Curd, MD
The Affordable Care Act stunts the growth of these institutions, but will quality of care and competition suffer as a result?